{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:16:07Z","timestamp":1775578567609,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s11095-013-1287-x","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T17:23:14Z","timestamp":1390324994000},"page":"1834-1845","source":"Crossref","is-referenced-by-count":60,"title":["Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles after Vaginal Delivery in Mice"],"prefix":"10.1007","volume":"31","author":[{"given":"Jos\u00e9","family":"das Neves","sequence":"first","affiliation":[]},{"given":"Francisca","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Andrade","sequence":"additional","affiliation":[]},{"given":"Mansoor","family":"Amiji","sequence":"additional","affiliation":[]},{"given":"Maria Fernanda","family":"Bahia","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-med-050911-163701","volume":"64","author":"J Baeten","year":"2013","unstructured":"Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med. 2013;64:219\u201332.","journal-title":"Annu Rev Med"},{"issue":"4","key":"1287_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bpobgyn.2012.01.010","volume":"26","author":"SS Abdool Karim","year":"2012","unstructured":"Abdool Karim SS, Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):427\u201339.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5996","key":"1287_CR3","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science"},{"issue":"9787","key":"1287_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","volume":"378","author":"SS Abdool Karim","year":"2011","unstructured":"Abdool Karim SS, Kashuba AD, Werner L, Abdool Karim Q. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279\u201381.","journal-title":"Lancet"},{"issue":"1","key":"1287_CR5","doi-asserted-by":"crossref","first-page":"e16475","DOI":"10.1371\/journal.pone.0016475","volume":"6","author":"MJ Keller","year":"2011","unstructured":"Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One. 2011;6(1):e16475.","journal-title":"PLoS One"},{"issue":"2","key":"1287_CR6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.05842-11","volume":"86","author":"C Dobard","year":"2012","unstructured":"Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol. 2012;86(2):718\u201325.","journal-title":"J Virol"},{"issue":"7","key":"1287_CR7","doi-asserted-by":"crossref","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","volume":"7","author":"S Duwal","year":"2012","unstructured":"Duwal S, Schutte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One. 2012;7(7):e40382.","journal-title":"PLoS One"},{"issue":"3","key":"1287_CR8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1128\/AAC.00330-07","volume":"52","author":"JP Nuttall","year":"2008","unstructured":"Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother. 2008;52(3):909\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1287_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3181e3293a","volume":"55","author":"AM Nel","year":"2010","unstructured":"Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010;55(2):161\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1287_CR10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2009.0227","volume":"26","author":"AM Nel","year":"2010","unstructured":"Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses. 2010;26(11):1181\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"1287_CR11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0b013e3181acb536","volume":"51","author":"A Nel","year":"2009","unstructured":"Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(4):416\u201323.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1287_CR12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","volume":"25","author":"J Romano","year":"2009","unstructured":"Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25(5):483\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"1287_CR13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.contraception.2007.04.013","volume":"76","author":"E Hardy","year":"2007","unstructured":"Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception. 2007;76(2):126\u201331.","journal-title":"Contraception"},{"issue":"12","key":"1287_CR14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/cid\/cir684","volume":"53","author":"CB Hurt","year":"2011","unstructured":"Hurt CB, Eron Jr JJ, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12):1265\u201370.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1287_CR15","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","volume":"8","author":"CW Hendrix","year":"2013","unstructured":"Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1):e55013.","journal-title":"PLoS One"},{"issue":"4\u20135","key":"1287_CR16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","volume":"62","author":"J Neves das","year":"2010","unstructured":"das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS. Adv Drug Deliv Rev. 2010;62(4\u20135):458\u201377.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1287_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425240903338055","volume":"7","author":"R Mallipeddi","year":"2010","unstructured":"Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010;7(1):37\u201348.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"1287_CR18","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1021\/mp300408m","volume":"9","author":"J Neves das","year":"2012","unstructured":"das Neves J, Rocha CM, Gon\u00e7alves MP, Carrier RL, Amiji M, Bahia MF, et al. Interactions of microbicide nanoparticles with a simulated vaginal fluid. Mol Pharm. 2012;9(11):3347\u201356.","journal-title":"Mol Pharm"},{"issue":"6","key":"1287_CR19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","volume":"29","author":"J Neves das","year":"2012","unstructured":"das Neves J, Michiels J, Arien KK, Vanham G, Amiji M, Bahia MF, et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res. 2012;29(6):1468\u201384.","journal-title":"Pharm Res"},{"issue":"7","key":"1287_CR20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp4002365","volume":"10","author":"J Neves das","year":"2013","unstructured":"das Neves J, Ara\u00fajo F, Andrade F, Michiels J, Ari\u00ebn KK, Vanham G, et al. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine. Mol Pharm. 2013;10(7):2793\u2013807.","journal-title":"Mol Pharm"},{"issue":"2","key":"1287_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpba.2010.01.007","volume":"52","author":"J Neves das","year":"2010","unstructured":"das Neves J, Sarmento B, Amiji MM, Bahia MF. Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles. J Pharm Biomed Anal. 2010;52(2):167\u201372.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"1287_CR22","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1128\/AAC.48.5.1837-1847.2004","volume":"48","author":"BJ Catalone","year":"2004","unstructured":"Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother. 2004;48(5):1837\u201347.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"1287_CR23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijpharm.2008.04.038","volume":"360","author":"T Kanazawa","year":"2008","unstructured":"Kanazawa T, Takashima Y, Hirayama S, Okada H. Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int J Pharm. 2008;360(1\u20132):164\u201370.","journal-title":"Int J Pharm"},{"issue":"6","key":"1287_CR24","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/mp400087y","volume":"10","author":"LM Ensign","year":"2013","unstructured":"Ensign LM, Henning A, Schneider C, Maisel K, Wang YY, Porosoff MD, et al. Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm. 2013;10(6):2176\u201382.","journal-title":"Mol Pharm"},{"issue":"1","key":"1287_CR25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1095\/biolreprod54.1.264","volume":"54","author":"JK Sherwood","year":"1996","unstructured":"Sherwood JK, Zeitlin L, Chen X, Whaley KJ, Cone RA, Saltzman WM. Residence half-life of IgG administered topically to the mouse vagina. Biol Reprod. 1996;54(1):264\u20139.","journal-title":"Biol Reprod"},{"issue":"2","key":"1287_CR26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2011.06.036","volume":"156","author":"Y Cu","year":"2011","unstructured":"Cu Y, Booth CJ, Saltzman WM. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release. 2011;156(2):258\u201364.","journal-title":"J Control Release"},{"key":"1287_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2012.10.034","volume":"911","author":"J Neves das","year":"2012","unstructured":"das Neves J, Sarmento B, Amiji M, Bahia MF. Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;911:76\u201383.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"1287_CR28","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","volume":"104","author":"SK Lai","year":"2007","unstructured":"Lai SK, O\u2019Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1287_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11095-008-9765-2","volume":"26","author":"AS Ham","year":"2009","unstructured":"Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res. 2009;26(3):502\u201311.","journal-title":"Pharm Res"},{"issue":"6","key":"1287_CR30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nmat2444","volume":"8","author":"KA Woodrow","year":"2009","unstructured":"Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8(6):526\u201333.","journal-title":"Nat Mater"},{"issue":"11","key":"1287_CR31","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","volume":"23","author":"LK Shah","year":"2006","unstructured":"Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS. Pharm Res. 2006;23(11):2638\u201345.","journal-title":"Pharm Res"},{"issue":"2","key":"1287_CR32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2013.08.049","volume":"456","author":"J Neves das","year":"2013","unstructured":"das Neves J, Amiji M, Bahia MF, Sarmento B. Assessing the physical-chemical properties and stability of dapivirine-loaded polymeric nanoparticles. Int J Pharm. 2013;456(2):307\u201314.","journal-title":"Int J Pharm"},{"issue":"6","key":"1287_CR33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri2302","volume":"8","author":"F Hladik","year":"2008","unstructured":"Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008;8(6):447\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1287_CR34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/mp8001254","volume":"6","author":"Y Cu","year":"2009","unstructured":"Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm. 2009;6(1):173\u201381.","journal-title":"Mol Pharm"},{"issue":"11","key":"1287_CR35","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/anie.201006849","volume":"50","author":"M Yang","year":"2011","unstructured":"Yang M, Lai SK, Wang YY, Zhong W, Happe C, Zhang M, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl. 2011;50(11):2597\u2013600.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"138","key":"1287_CR36","doi-asserted-by":"crossref","first-page":"138ra79","DOI":"10.1126\/scitranslmed.3003453","volume":"4","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79.","journal-title":"Sci Transl Med"},{"issue":"21","key":"1287_CR37","doi-asserted-by":"crossref","first-page":"11196","DOI":"10.1128\/JVI.01899-08","volume":"83","author":"SK Lai","year":"2009","unstructured":"Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol. 2009;83(21):11196\u2013200.","journal-title":"J Virol"},{"issue":"4","key":"1287_CR38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/wnan.144","volume":"3","author":"J Neves das","year":"2011","unstructured":"das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):389\u201399.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"1287_CR39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1166\/jbn.2011.1194","volume":"7","author":"R Malik","year":"2011","unstructured":"Malik R, Maikhuri JP, Gupta G, Misra A. Biodegradable nanoparticles in the murine vagina: trans-cervical retrograde transport and induction of proinflammatory cytokines. J Biomed Nanotechnol. 2011;7(1):45\u20136.","journal-title":"J Biomed Nanotechnol"},{"issue":"4","key":"1287_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bpobgyn.2012.01.004","volume":"26","author":"JL Adams","year":"2012","unstructured":"Adams JL, Kashuba AD. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):451\u201362.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3\u20134","key":"1287_CR41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejps.2009.02.022","volume":"37","author":"Y Liu","year":"2009","unstructured":"Liu Y, Zhu YY, Wei G, Lu WY. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur J Pharm Sci. 2009;37(3\u20134):306\u201312.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1287_CR42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/humrep\/12.5.1073","volume":"12","author":"C Bulletti","year":"1997","unstructured":"Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073\u20139.","journal-title":"Hum Reprod"},{"issue":"1","key":"1287_CR43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.00597-11","volume":"56","author":"J Nuttall","year":"2012","unstructured":"Nuttall J, Kashuba A, Wang R, White N, Allen P, Roberts J, et al. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother. 2012;56(1):103\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1287_CR44","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135.","journal-title":"Pharm Res"},{"issue":"11","key":"1287_CR45","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1089\/aid.2013.0122","volume":"29","author":"J Romano","year":"2013","unstructured":"Romano J, Kashuba A, Becker S, Cummins J, Turpin J. Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)\/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses. 2013;29(11):1418\u201327.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"1287_CR46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157016212799304715","volume":"10","author":"RS Veazey","year":"2012","unstructured":"Veazey RS, Shattock RJ, Klasse PJ, Moore JP. Animal models for microbicide studies. Curr HIV Res. 2012;10(1):79\u201387.","journal-title":"Curr HIV Res"},{"issue":"1","key":"1287_CR47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.00597-11","volume":"56","author":"J Nuttall","year":"2011","unstructured":"Nuttall J, Kashuba A, Wang R, White N, Allen P, Roberts J, et al. The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to Rhesus macaques. Antimicrob Agents Chemother. 2011;56(1):103\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1287_CR48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01156-08","volume":"53","author":"P Fletcher","year":"2009","unstructured":"Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53(2):487\u201395.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1287_CR49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/00002030-200307250-00003","volume":"17","author":"S Fabio Di","year":"2003","unstructured":"Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, Binelli A, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS. 2003;17(11):1597\u2013604.","journal-title":"AIDS"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1287-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-013-1287-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1287-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T17:52:17Z","timestamp":1565113937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-013-1287-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s11095-013-1287-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}